The Pharma Data

OCTOBER 9, 2021

Alzheimer’s is the most common form of madness, which presently affects farther than 55 million people worldwide, and is projected to reach 78 million by 2030. trillion per space by 2030. Much 10 million people widely are diagnosed with Notice each space.

Disease 52

Disease FDA Therapies Trials 52

Drug Target Review

SEPTEMBER 22, 2023

The substantial value of organoids is becoming increasingly recognised by supportive government initiatives developing novel drugs, with a growth rate of 22 percent between 2023 and 2030 and a market size predicted to reach over US $6.5 billion by 2030. CRISPR engineering in organoids for gene repair and disease modelling.

Clinical Research 116

Clinical Research Research Drug Development Science 116

The Pharma Data

NOVEMBER 2, 2020

million people were treated for lymphatic filariasis (LF) in 38 countries that implemented mass drug administration (MDA) of populations at risk of the disease, as recommended by the World Health Organization (WHO). million people no longer require MDA for this debilitating parasitic disease. Setting sights on 2030.

Packaging 52

Packaging Disease Treatment Drugs 52

The Pharma Data

JANUARY 26, 2021

27, 2021 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer’s disease. STOCKHOLM , Jan. About BioArctic AB.

Disease 40

Disease Pharmaceutical Companies Treatment Licensing 40

The Pharma Data

JULY 27, 2021

AbbVie (NYSE: ABBV) and Calico Life Sciences today announced an extension of their leading-edge collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. This is the second extension of the collaboration originally established in 2014. Levinson, Ph.D.,

Disease 52

Disease Science Therapies Production 52

LifeSciVC

APRIL 26, 2024

Further, this lemming challenge has also moved well beyond oncology – think of all the “not-so-fast follower” autoimmune programs or metabolic disease stories. This has long been a feature of biopharma (see 2012 and 2016 posts on oncology and immune-oncology , respectively), but has been exacerbated by the creation of so many new companies.

DNA 124

DNA Science Marketing Clinical Trials 124

The Pharma Data

MARCH 9, 2021

New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer’s & Parkinson Diseases 2021 (AD/PD 2021), March 9-14, 2021. vice president of Alzheimer’s disease development unit, Eli Lilly and Company.

Disease 40

Disease International Research Therapies 40

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). Dementia due to Alzheimer’s disease is the most common form of dementia, accounting for 60 to 80 percent of all cases 1.

Therapies 40

Therapies Disease Treatment FDA Approval 40

The Pharma Data

FEBRUARY 21, 2022

Such success stories are encouraging and help us to eliminate more diseases in our Region.”. The disease. Trachoma is a devastating eye disease caused by infection with the bacterium Chlamydia trachomatis. To eliminate trachoma, WHO recommends the SAFE strategy 2 to achieve elimination of trachoma as a public health problem.

Disease 52

Disease Treatment International Drugs 52

Drug Target Review

DECEMBER 4, 2023

What’s more, investment in this sector is predicted to rise by 70 percent by 2030. Tailoring medical care to a patient’s unique genetic makeup, alongside the close analysis of disease progression, leads to more effective treatments, reduced side effects and faster diagnoses.

Treatment 105

Treatment Science DNA Doctors 105

The Pharma Data

MARCH 13, 2021

Further, prespecified exploratory analyses showed donanemab slowed the accumulation of tau across key brain regions in patients affected by Alzheimer’s disease. “This is the first late-stage study in Alzheimer’s disease to meet its primary endpoint at the primary analysis. Apostolova, M.D.,

Disease 40

Disease Trials Treatment Medical Schools 40

New Drug Approvals

JANUARY 31, 2024

In addition to hyperlipidemia and type 2 diabetes, a marked increase in the prevalence of non-alcoholic fatty liver disease (NAFLD) has occurred. Preparation of benzoic acid derivatives for treatment of metabolic and liver diseases. Current drugs that treat hyperlipidemia (e.g., twitter +919321316780 call whatsaapp EMAIL.

Treatment 52

Treatment Disease Pharmaceuticals Drugs 52

The Premier Consulting Blog

MAY 4, 2023

billion in 2022 and is expected to grow approximately eight percent from 2023 to 2030 [1]. Ophthalmic drugs market size, share & trends analysis report by drug class, by disease (dry eye, glaucoma), by dosage form, by route of administration, by product type (prescription, OTC), by region, and segment forecasts, 2022-2030.

FDA 52

FDA Packaging Regulations Compliance 52

The Pharma Data

MAY 17, 2023

“Following Benin’s and Mali’s success, trachoma remains endemic in 23 countries in WHO’s African Region, bringing us a step closer towards the elimination target for trachoma set in the road map for neglected tropical diseases 2021–2030.” The disease is caused by infection with the bacterium Chlamydia trachomatis.

Disease 40

Disease International Treatment 40

The Pharma Data

MAY 4, 2021

Improving access to quality health care for 30 million people globally living in limited resource settings annually by 2030 through the Lilly 30×30 initiative. Environment (by 2030). Highlights of Lilly ‘s ESG commitments include: Access and Affordability. To learn more about Lilly , please visit us at? www.lilly.com ?and?

Government 52

Government Disease Production 52

The Pharma Data

NOVEMBER 11, 2021

Making Further Health has committed to appreciatively impact the lives and health of 50 million people and engage Boehringer Ingelheim workers by 2030. Centers for Disease Control and Prevention. Atlanta, GA Centers for Disease Control and Prevention,U.S.Dept. National Diabetes Statistics Report, 2020.

International 40

International Disease 40

The Pharma Data

MARCH 2, 2021

Senior Vice President and Global Head of Cardiometabolic Diseases Research, Boehringer Ingelheim. Obesity is a complex chronic disease that requires long-term management. It is among the leading risk factors for several cardio-metabolic diseases, such as heart disease, ischemic stroke, liver diseases incl.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

The Pharma Data

JULY 15, 2021

Trial will include participants at risk for cognitive and functional decline related to Alzheimer’s disease. TRAILBLAZER-ALZ 3 will evaluate whether treatment with donanemab can slow the clinical progression of Alzheimer’s disease in trial participants. vice president of pain and neurodegeneration, Lilly.

Trials 52

Trials Therapies Clinical Trials Disease 52

The Pharma Data

JULY 29, 2021

In the second, Lilly shared data showing that treatment with donanemab drives a rapid reduction of a biomarker reflecting Alzheimer’s disease pathology, plasma P-tau217, which was detected within 12 weeks. Visit LillyMemoryTrials.com for additional information on enrolling in Alzheimer’s disease trials.

Disease 52

Disease Treatment Pharmacokinetics Trials 52

Drug Target Review

OCTOBER 1, 2024

Considering the Italian landscape, for example, it is my opinion that resources allocated by the National Recovery and Resilience Plan (PNRR) for gender equality represent a unique opportunity to aspire to achieve the sustainable development objectives set out in the 2030 Agenda.

Doctors 97

Doctors Therapies Science Pharma Companies 97

The Pharma Data

FEBRUARY 21, 2022

In the area of cardiovascular disease, Bayer is delivering on its late-stage pipeline including recent launches of Kerendia™ (finerenone) and Verquvo™ (vericiguat). “We Our scientific leadership in the area of cardiovascular diseases advances our mission to provide better treatment options for patients in need.”.

Clinical Trials 52

Clinical Trials Small Molecule Clinical Development Disease 52

The Pharma Data

NOVEMBER 1, 2020

MS is an autoimmune, inflammatory disease of the central nervous system. billion by 2030 2. BTK inhibitors have the potential to transform the treatment paradigm of autoimmune diseases including MS. We strategically focus on lymphoma, solid tumors, and autoimmune disease with high unmet medical needs in China and worldwide.

Clinical Trials 40

Clinical Trials Trials FDA Treatment 40

Vial

APRIL 18, 2024

Yet, hereditary and age-related retinal diseases present challenges, often leading to progressive vision loss and potential blindness. Market research indicates significant growth in the ophthalmic clinical trials market, driven by increased disease prevalence, demand for ocular treatments, and rising research funding.

Clinical Trials 52

Clinical Trials Trials Treatment Clinical Research 52

The Pharma Data

MAY 26, 2023

With our leading portfolio of medicines in lung cancer, our ambition is to have the right AstraZeneca medicine for more than half of all patients with this disease by 2030. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Therapies 40

Therapies Trials Treatment Disease 40

Vial

MAY 20, 2024

billion by 2030 at a compound annual growth rate (CAGR) of 7.5% The clinical phase of drug research is especially important because it tests the findings from preclinical studies in real-life conditions within the target disease population with human volunteers. between 2024 and 2030. What is a Pre-Clinical CRO?

Clinical Research 52

Clinical Research Clinical Trials Research Trials 52

The Pharma Data

NOVEMBER 22, 2020

This patent completes the Ezeprogind related patents granted in the USA for composition of matter (US 9,562,018) and therapeutic uses in the treatment of Alzheimer’s and Parkinson’s diseases (US 10,537,569). Alzprotect is committed to the development of innovative therapeutic solutions in the field of neurodegenerative diseases.

Drugs 40

Drugs Disease Clinical Trials Licensing 40

The Pharma Data

MAY 3, 2021

Chronic disease care and management. “ Lilly is committed to helping address systemic inequities in health, including for those with non-communicable diseases such as diabetes, that too often have devastating effects on the lives of historically marginalized people,” said David A. www.lilly.com ?and? www.lilly.com/news.?I-LLY.

Clinical Trials 40

Clinical Trials Disease Therapies Trials 40

DrugBank

FEBRUARY 19, 2025

billion by 2030, the sector is witnessing a shift in how drugs are conceived, developed, and tested.  Historically, the target identification process has been fraught with challenges due to the sheer complexity of diseases and the large volume of data that needs to be analyzed. billion in 2023 to $7.9

Clinical Trials 52

Clinical Trials Drugs Trials Treatment 52

The Pharma Data

MARCH 2, 2021

This biological solution responds to Bayer’s commitment to help reduce the environmental impact of crop protection by 30% by 2030 without reducing crop yields. The launch of Vynyty Citrus ® at this year’s SHE2021 event coincides with 2021 being designated as the International Year of Fruits and Vegetables by the United Nations.

Production 52

Production International Science Licensing 52

The Pharma Data

SEPTEMBER 16, 2020

We’re currently working to support global health efforts to address diseases like malaria and leprosy, to continue novel research into tropical diseases, and to ensure access to our new medicines in low- and middle-income countries,” said Vas Narasimhan, CEO of Novartis.

Therapies 52

Therapies Regulations Government Disease 52

Vial

FEBRUARY 8, 2024

billion in 2030. Research teams have applied AI in disease detection, data collection using wearable devices, data processing for DCTs, data mining and patient recruitment, and biosimulation, amongst others. The demand for clinical trial services is growing steadily, with analysts estimating the global market size at US$ 84.7

Clinical Trials 52

Clinical Trials Trials Clinical Research Research 52

FDA Law Blog: Biosimilars

DECEMBER 11, 2023

24] These submissions all related to a single disease. FDA’s own estimates would result in an influx of premarket submissions, in a six-month period, that would be 40 times greater than the number of COVID submissions and related to an extraordinarily diverse set of diseases and conditions.

FDA 69

FDA Laboratories Regulations Production 69

Agency IQ

MARCH 7, 2024

government recently extended that recognition through 2028 for medical devices and 2030 for IVDs. MHRA launched the pilot in late 2023 and ultimately chose eight products with different technologies that address life-threatening diseases with no equivalent solutions that also support the U.K.’s s Life Sciences Vision.

Regulations 40

Regulations International Production Government 40

The Pharma Data

AUGUST 5, 2021

Food and Drug Administration for the treatment of adult patients with chronic kidney disease and type 2 diabetes. Through this amendment, Bayer has emphasized its commitment to achieving climate neutrality by 2030 and its holistic sustainability strategy. The latter product was approved in July by the U.S.

Production 52

Production Pharmaceuticals Science Therapies 52

PPD

APRIL 14, 2025

Last year, an American Heart Association presidential advisory for the first time formally identified the strong connections between cardiovascular disease (CVD), kidney disease, Type 2 diabetes and obesity as reason to define cardiovascular-kidney-metabolic (CKM) syndrome.

Clinical Trials 52

Clinical Trials Trials Clinical Development Disease 52

The Pharma Data

NOVEMBER 12, 2020

Committee A, which focuses on programme and budget matters, decided to recommend the adoption of the first-ever resolution on meningitis, which would approve a global roadmap to defeat meningitis by 2030 – a disease that kills 300,000 people annually and leaves one in five of those affected with devastating long-term consequences.

Disease 52

Disease Treatment 52

DrugBank

AUGUST 9, 2024

Humira , AbbVie's monoclonal antibody for autoimmune diseases, generated over $20 billion in annual revenue at its peak before losing patent exclusivity in 2023.  This exponential growth is primarily fueled by the escalating global burden of chronic diseases. billion by 2030. trillion by 2028.

Pharmaceuticals 98

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 98